Seoul, South Korea

Byung-Nak Ahn

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2009-2013

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Byung-Nak Ahn: Innovator in Pharmaceutical Chemistry

Introduction

Byung-Nak Ahn is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 6 patents to his name, Ahn's work focuses on innovative solutions for proton pump inhibition.

Latest Patents

Ahn's latest patents include the development of pyrrolo[3,2-C] pyridine derivatives and processes for their preparation. This invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts, which exhibit excellent proton pump inhibition effects. These compounds possess the ability to achieve a reversible proton pump inhibitory effect, making them valuable in therapeutic applications. Another significant patent involves pyrrolo[2,3-C]pyridine derivatives, which also demonstrate similar proton pump inhibition properties and potential for pharmaceutical use.

Career Highlights

Throughout his career, Ahn has worked with notable companies in the pharmaceutical industry, including Yuhan Corporation and Whan in Pharmaceutical Co., Ltd. His expertise in the field has led to advancements in drug development and therapeutic solutions.

Collaborations

Ahn has collaborated with esteemed colleagues such as Jae-Gyu Kim and Hyouk-Woo Lee, contributing to the advancement of pharmaceutical research and innovation.

Conclusion

Byung-Nak Ahn's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the field. His work continues to influence the development of effective therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…